The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Palliative Radiotherapy Protocol in Head and Neck Cancer
Official Title: Palliative Radiotherapy for Advanced Head and Neck Carcinomas, a Phase II Study
Study ID: NCT02460471
Brief Summary: Phase II prospective study or Palliative Radiotherapy of 25 Gy in 5 fractions, Intensity Modulated, for frail patients with incurable head and neck cancer. Comprehensive Quality of life (QLQ-C30, head and neck module, QLQ C15 PAL) and toxicity data (CTCAE v 4.0) collected.
Detailed Description: Patients deemed too frail for radical treatment or incurable because of tumour extension, as determined by an experienced tumour board, were eligible for this study of palliative radiotherapy delivered by intensity modulation, 25 Gy in 5 daily fractions over one week. This study was conducted in two academic centers.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada
Name: Bernard Fortin, MD MSc
Affiliation: Maisonneuve Rosemont Hospital, University of Montreal
Role: PRINCIPAL_INVESTIGATOR